News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
343,871 Results
Type
Article (20886)
Company Profile (141)
Press Release (322833)
Multimedia
Podcasts (106)
Webinars (17)
Section
Business (105837)
Career Advice (890)
Deals (18626)
Drug Delivery (105)
Drug Development (51014)
Employer Resources (80)
FDA (7825)
Job Trends (7815)
News (186797)
Policy (17465)
Tag
Academia (736)
Accelerated approval (14)
Adcomms (22)
Allergies (73)
Alliances (27971)
ALS (82)
Alzheimer's disease (767)
Antibody-drug conjugate (ADC) (178)
Approvals (7953)
Artificial intelligence (253)
Autoimmune disease (60)
Automation (12)
Bankruptcy (178)
Best Places to Work (5555)
BIOSECURE Act (14)
Biosimilars (156)
Biotechnology (60)
Bladder cancer (70)
Brain cancer (32)
Breast cancer (231)
Cancer (2103)
Cardiovascular disease (217)
Career advice (736)
Career pathing (24)
CAR-T (99)
CDC (14)
Cell therapy (259)
Cervical cancer (11)
Clinical research (44478)
Collaboration (865)
Company closure (1)
Compensation (335)
Complete response letters (47)
COVID-19 (1144)
CRISPR (45)
C-suite (449)
Cystic fibrosis (85)
Data (3000)
Decentralized trials (2)
Denatured (26)
Depression (70)
Diabetes (229)
Diagnostics (1878)
Digital health (14)
Diversity (8)
Diversity, equity & inclusion (22)
Drug discovery (152)
Drug pricing (181)
Drug shortages (33)
Duchenne muscular dystrophy (124)
Earnings (40753)
Editorial (43)
Employer branding (10)
Employer resources (78)
Events (50648)
Executive appointments (608)
FDA (9209)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (3)
Frontotemporal dementia (4)
Funding (593)
Gene editing (82)
Generative AI (28)
Gene therapy (242)
GLP-1 (775)
Government (1999)
Grass and pollen (4)
Guidances (202)
Healthcare (5927)
HIV (25)
Huntington's disease (20)
IgA nephropathy (55)
Immunology and inflammation (154)
Immuno-oncology (23)
Indications (49)
Infectious disease (1266)
Inflammatory bowel disease (110)
Inflation Reduction Act (11)
Influenza (40)
Intellectual property (119)
Interviews (118)
IPO (7419)
IRA (52)
Job creations (2442)
Job search strategy (653)
Kidney cancer (10)
Labor market (58)
Layoffs (340)
Leadership (26)
Legal (4149)
Liver cancer (35)
Longevity (7)
Lung cancer (315)
Lymphoma (195)
Machine learning (19)
Management (31)
Manufacturing (456)
MASH (96)
Medical device (1998)
Medtech (2003)
Mergers & acquisitions (11680)
Metabolic disorders (792)
Multiple sclerosis (87)
NASH (20)
Neurodegenerative disease (139)
Neuropsychiatric disorders (57)
Neuroscience (1403)
NextGen: Class of 2025 (2361)
Non-profit (919)
Now hiring (41)
Obesity (456)
Opinion (226)
Ovarian cancer (58)
Pain (126)
Pancreatic cancer (82)
Parkinson's disease (141)
Partnered (16)
Patents (255)
Patient recruitment (186)
Peanut (19)
People (34310)
Pharmaceutical (76)
Pharmacy benefit managers (30)
Phase I (13990)
Phase II (18769)
Phase III (15100)
Pipeline (2116)
Policy (218)
Postmarket research (1619)
Preclinical (4914)
Press Release (29)
Prostate cancer (120)
Psychedelics (24)
Radiopharmaceuticals (171)
Rare diseases (448)
Real estate (3202)
Recruiting (33)
Regulatory (13477)
Reports (25)
Research institute (832)
Resumes & cover letters (140)
Rett syndrome (3)
RNA editing (9)
RSV (40)
Schizophrenia (108)
Series A (105)
Series B (72)
Service/supplier (7)
Sickle cell disease (61)
Special edition (21)
Spinal muscular atrophy (115)
Sponsored (18)
Startups (2034)
State (2)
Stomach cancer (11)
Supply chain (69)
Tariffs (91)
The Weekly (78)
Vaccines (382)
Venture capital (55)
Weight loss (340)
Women's health (32)
Worklife (8)
Date
Today (47)
Last 7 days (317)
Last 30 days (1307)
Last 365 days (15536)
2025 (15052)
2024 (17674)
2023 (19641)
2022 (25873)
2021 (26648)
2020 (24882)
2019 (20062)
2018 (15599)
2017 (17254)
2016 (16209)
2015 (18805)
2014 (14790)
2013 (12553)
2012 (13483)
2011 (13817)
2010 (12739)
Location
Africa (414)
Alabama (39)
Alaska (1)
Arizona (88)
Arkansas (8)
Asia (25729)
Australia (3308)
California (4418)
Canada (1713)
China (654)
Colorado (175)
Connecticut (180)
Delaware (165)
Europe (53151)
Florida (766)
Georgia (94)
Hawaii (1)
Idaho (18)
Illinois (398)
India (44)
Indiana (275)
Iowa (3)
Japan (270)
Kansas (81)
Kentucky (28)
Louisiana (5)
Maine (4)
Maryland (572)
Massachusetts (3595)
Michigan (62)
Minnesota (225)
Mississippi (3)
Missouri (40)
Montana (12)
Nebraska (12)
Nevada (35)
New Hampshire (8)
New Jersey (1744)
New Mexico (21)
New York (1219)
North Carolina (735)
North Dakota (2)
Northern California (2030)
Ohio (117)
Oklahoma (8)
Oregon (22)
Pennsylvania (985)
Puerto Rico (17)
Rhode Island (25)
South America (611)
South Carolina (10)
Southern California (1868)
Tennessee (61)
Texas (600)
United States (16919)
Utah (90)
Virginia (162)
Washington D.C. (57)
Washington State (349)
West Virginia (1)
Wisconsin (43)
Wyoming (1)
343,871 Results for "lantern pharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Lantern Pharma Reports Third Quarter 2025 Financial Results and Provides Business Updates
November 14, 2025
·
19 min read
Press Releases
Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2025
October 27, 2025
·
5 min read
Press Releases
Lantern Pharma to Report Third Quarter 2025 Operating & Financial Results on November 13th, 2025 at 9:00 a.m. ET
November 7, 2025
·
5 min read
Press Releases
Lantern Pharma Reports Second Quarter 2025 Financial Results and Business Updates
August 13, 2025
·
18 min read
Press Releases
Lantern Pharma Announces Appointment of Dr. Lee Schalop to Board of Directors
July 29, 2025
·
5 min read
Press Releases
Lantern Pharma Reports Additional Positive LP-184 Phase 1a Results Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients as Company Advances Precision Oncology Program into Multiple Biomarker-Guided Phase 1b/2 Trials
December 4, 2025
·
14 min read
Press Releases
Lantern Pharma Presents LP-284 Clinical Data at 25th LL&M Congress, Highlighting Complete Response in Therapeutically Exhausted DLBCL Patient & Therapeutic Potential in Advanced B-Cell Cancers.
October 29, 2025
·
11 min read
Press Releases
Lantern Pharma Announces Completion of Type C Meeting with FDA, Providing Clarity on Regulatory Pathway for Pediatric CNS Cancer Trial
September 4, 2025
·
6 min read
Press Releases
Lantern Pharma’s LP-184 Phase 1a Clinical Trial Achieves All Primary Endpoints with Robust Safety Profile and Promising Antitumor Activity in Multiple Advanced Solid Tumors
September 17, 2025
·
9 min read
Press Releases
Lantern Pharma Completes Targeted Enrollment for Lung Cancer Phase 2 Harmonic™ Clinical Trial in Japan for LP-300
August 1, 2025
·
9 min read
1 of 34,388
Next
